Search clinical trials for: transporter

Total 1528 results

Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Boehringer Ingelheim

Completed

Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

Healthy

Russian Federation
Uppsala University
AstraZeneca; Uppsala University Hospital

Completed

Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight (Dapalost)

Obesity

Sweden
AstraZeneca
Bristol-Myers Squibb

Completed

Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States, Canada, Mexico, Puerto Rico
Lexicon Pharmaceuticals

Completed

PK Study of Sotagliflozin in Subjects With Hepatic Impairment

Healthy | Hepatic Impairment

United States
University of Utah

Completed

Nutrient Regulation of Amino Acid Transporters in Aging Human Skeletal Muscle

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

Diabetes Mellitus, Type 2

United States, Australia, Germany, Canada, France
AstraZeneca
Bristol-Myers Squibb

Completed

A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects

Diabetes Mellitus, Type 2

United States
Korea University Anam Hospital
AstraZeneca

Unknown

Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes

Diabetes Mellitus, Type II

Korea, Republic of
AstraZeneca
Bristol-Myers Squibb

Completed

Renal Impairment in Type 2 Diabetic Subjects

Diabetes Mellitus, Type 2

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects

Diabetes Mellitus, Type 2

Argentina
AstraZeneca
Bristol-Myers Squibb

Completed

Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects (ULDS)

Type 2 Diabetes

United States
AstraZeneca
Bristol-Myers Squibb

Terminated

Renal Mechanism of Action/Splay vs. TmG (MOA)

Diabetes, NOS

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

Type 2 Diabetes Mellitus (T2DM)

United States
AstraZeneca
Bristol-Myers Squibb

Terminated

Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
Janssen Research & Development, LLC

Completed

Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

Obesity

United States
Baylor College of Medicine
National Institute on Drug Abuse (NIDA)

Completed

DOX as a Potential Treatment for Methamphetamine Dependence (DOX-Meth)

Substance-Related Disorders

United States
Medical University of Vienna

Unknown

Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy Metabolism

Type 2 Diabetes | Metabolically Healthy Controls

Austria
Boehringer Ingelheim
Eli Lilly and Company

Completed

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, France, Israel, Mexico, South Africa
Rambam Health Care Campus

Completed

Apomorphine Effects on Experimental Pain

Healthy

Israel
Medical University of Lodz

Completed

Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia (PULSAR)

Schizophrenia

Poland
AstraZeneca
Monash University

Terminated

forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP) (forREAL)

Type 2 Diabetes

Australia
Bayer

Completed

Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate

Healthy Volunteers | Pharmacokinetics | Drug Interaction

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Argentina, Austria, Canada, Colombia, Czech Republic, Finland, Hong Kong, India, Italy, Malaysia, Mexico, Netherlands, Norway, Philippines, Portugal, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, United...
University of Pittsburgh
National Institute of Neurological Disorders and Stroke (NINDS); National Institutes...

Completed

Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury (Pro-NAC)

Pediatric Traumatic Brain Injury

United States
University Hospital, Basel, Switzerland

Completed

Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study (DIVE)

Inappropriate ADH Syndrome

Switzerland
Chong Kun Dang Pharmaceutical

Unknown

Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin

Diabetes Mellitus, Type II

Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers

Healthy

India
Janssen Research & Development, LLC

Completed

A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

Diabetes Mellitus, Type 1

United States, Canada
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Australia, Brazil, Canada, El Salvador, France, Korea, Republic of, New Zealand, Norway, Spain, Taiwan
AstraZeneca
Bristol-Myers Squibb

Completed

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

Type 2 Diabetes Mellitus

Korea, Republic of, United States, Mexico, India, Puerto Rico, Russian Federation
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Investigate the Absorption, Metabolism, and Excretion of Canagliflozin (JNJ-28431754) in Healthy Male Volunteers

Healthy

Belgium
AstraZeneca

Completed

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

United States, Puerto Rico, Mexico, Russian Federation, Romania, Poland, Czech Republic, United Kingdom
Department of Medical Research, Lower Myanmar
Kangwon National University

Completed

Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar

Plasmodium Falciparum Malaria | Drug Resistance

Myanmar
University of British Columbia
Ultragenyx Pharmaceutical Inc

Unknown

Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome (Glut1C7)

Glucose Transporter Type 1 Deficiency Syndrome

Canada
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers

Healthy

Germany
University Hospital of North Norway
Nordlandssykehuset HF

Completed

Fructose Malabsorption in Northern Norway (FINN)

Irritable Bowel Syndrome | Fructose Malabsorption

Norway
Merck Sharp & Dohme LLC
Pfizer

Completed

Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)

Diabetes Mellitus, Type 2
AstraZeneca

Withdrawn

Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice (FLORA)

Diabetes Mellitus Type 2
Boehringer Ingelheim
Eli Lilly and Company

Completed

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Georgia, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Japan, Korea, Republic of, Malaysia and more
University Medical Center Goettingen

Completed

Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1 (PG-OCT)

Drug Metabolism | Membrane Transport

Germany
AstraZeneca

Completed

Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.

Type 2 Diabetes Mellitus

Japan

3

Subscribe